TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24079281

Group type: EXPERIMENTAL
Intervention: rosuvastatin (maximum dose of 10 mg for <10 years, 20 mg for older children)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: rosuvastatin
Number of subjects: 198
Study: 22140514

Group type: EXPERIMENTAL
Intervention: Internet CBT plus weekly telephone follow‐up
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Internet CBT only
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Weekly telephone follow‐up only
Number of subjects: 155

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 155
Study: 19549149

Group type: EXPERIMENTAL
Intervention: Bioplic (dimethacrylate‐based filling)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cavit (zinc oxide/calcium sulphate‐based cement)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Vidrion R (glass ionomer cement)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: IRM (zinc oxide/eugenol cement)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Vidrion R and Bioplic
Number of subjects: 10
Study: 17352821

Group type: EXPERIMENTAL
Intervention: Chronic right ventricular pacing in pediatric patients with complex congenital heart malformations
Number of subjects: 99

Group type: COMPARATOR
Intervention: Chronic right ventricular pacing in pediatric patients with or without structural heart disease
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Chronic right ventricular pacing
Number of subjects: 99
Study: 15569112

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg intravenously
Number of subjects: 25

Group type: COMPARATOR
Intervention: Pantoprazole 40 mg intravenously
Number of subjects: 25
Study: 10994933

Group type: EXPERIMENTAL
Intervention: Troponin I serum concentration in hypertensive patients with LVH
Number of subjects: 100

Group type: COMPARATOR
Intervention: Troponin I serum concentration in hypertensive patients without LVH
Number of subjects: 100

Group type: COMPARATOR
Intervention: Troponin I serum concentration in normal controls
Number of subjects: 100
Study: 9142772

Group type: EXPERIMENTAL
Intervention: Single daily dosing (SDD) of aminoglycosides
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multiple daily dosing of aminoglycosides
Number of subjects: 0
Study: 1728834

Group type: EXPERIMENTAL
Intervention: Mazindol
Number of subjects: 0
Study: 6704567

Group type: EXPERIMENTAL
Intervention: Active suction at -80 mmHg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Active suction at -40 mmHg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Underwater sealed drainage
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Patients with side effects during thoracocentesis
Number of subjects: 45

Group type: COMPARATOR
Intervention: Asymptomatic patients
Number of subjects: 45
Study: 30829925

Group type: EXPERIMENTAL
Intervention: Breastfeeding self‐management (BSM) intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 29428106

Group type: EXPERIMENTAL
Intervention: Postoperative octreotide (Group II)
Number of subjects: 104

Group type: COMPARATOR
Intervention: No postoperative octreotide (Group I)
Number of subjects: 104
Study: 26089554

Group type: EXPERIMENTAL
Intervention: Self‐directed online intervention
Number of subjects: 72

Group type: COMPARATOR
Intervention: 12‐week wait list (control)
Number of subjects: 72
Study: 1430080

Group type: EXPERIMENTAL
Intervention: 200 mg TB
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 600 mg TB
Number of subjects: 8
Study: 21689179

Group type: EXPERIMENTAL
Intervention: Extraction of primary canines
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Analgesics used
Number of subjects: 44

Group type: COMPARATOR
Intervention: Dental anxiety scale (DAS) assessment
Number of subjects: 44
Study: 19553094

Group type: EXPERIMENTAL
Intervention: Diet high in oat and wheat bread and potato (OWP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Rye bread and pasta (RP)
Number of subjects: 20
Study: 18482765

Group type: EXPERIMENTAL
Intervention: VH fibrin sealant (FS)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Sutured closure (SC)
Number of subjects: 150
Study: 15727506

Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 12880649

Group type: EXPERIMENTAL
Intervention: Concealment instruction (avoid talking about a certain topic)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral condition (no concealment instruction)
Number of subjects: 0
Study: 10327526

Group type: EXPERIMENTAL
Intervention: Statistical model prespecified for primary analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomization-based tests for no treatment effect
Number of subjects: 0
Study: 8890801

Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 605

Group type: COMPARATOR
Intervention: Aspirin (medication)
Number of subjects: 605

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 605
Study: 1676361

Group type: EXPERIMENTAL
Intervention: Antacids and/or histamine‐2‐receptor antagonists
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Stress ulcer prophylactic therapy titrated to achieve a gastric pH of 3.5 or greater
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sucralfate
Number of subjects: 48
Study: 159425

Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 10
Study: 31573379

Group type: EXPERIMENTAL
Intervention: Cannabis Use Disorder (CUD)
Number of subjects: 31272

Group type: EXPERIMENTAL
Intervention: CUD
Number of subjects: 31272

Group type: COMPARATOR
Intervention: Anxiety disorders
Number of subjects: 31272

Group type: COMPARATOR
Intervention: Depressive disorders
Number of subjects: 31272

Group type: COMPARATOR
Intervention: Tobacco use disorder
Number of subjects: 31272
Study: 31159786

Group type: EXPERIMENTAL
Intervention: News stories reported with spin
Number of subjects: 900

Group type: COMPARATOR
Intervention: News stories reported without spin
Number of subjects: 900
Study: 28492279

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Ketamine 0.2 mg/kg
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg/kg
Number of subjects: 71
Study: 25765952

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus cisplatin (GC)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Docetaxel plus cisplatin (DC)
Number of subjects: 136
Study: 23268837

Group type: EXPERIMENTAL
Intervention: Iloprost (a prostacyclin analog)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Iloprost
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 21115191

Group type: EXPERIMENTAL
Intervention: 60 Second Taste Gel
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Topex
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Zap
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: pH7 Gel (neutral fluoride agent)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Distilled water (control)
Number of subjects: 320
Study: 19900941

Group type: COMPARATOR
Intervention: Single-dose cruciferous diet
Number of subjects: 67

Group type: COMPARATOR
Intervention: Double-dose cruciferous diet
Number of subjects: 67

Group type: COMPARATOR
Intervention: Cruciferous-plus-apiaceous diet
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: GSTM1-null/GSTT1-null individuals
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Single-dose cruciferous diet in GSTM1-null/GSTT1-null individuals
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Double-dose cruciferous diet in GSTM1-null/GSTT1-null men
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Double-dose cruciferous diet in GSTM1+/GSTT1+ men
Number of subjects: 67
Study: 17045665

Group type: EXPERIMENTAL
Intervention: Interatrial block patients
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (no interatrial block)
Number of subjects: 51
Study: 16870070

Group type: EXPERIMENTAL
Intervention: Bisoprolol plus magnesium (Mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no combined study medication)
Number of subjects: 100
Study: 12825002

Group type: EXPERIMENTAL
Intervention: Midtrimester ultrasound (US) imaging
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Home uterine activity monitoring (HUAM)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Doppler velocimetry in high-risk pregnancy
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Short-term tocolysis
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Single-course antenatal corticosteroids (BMZ)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Thyroid-releasing hormone (TRH)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Fetal fibronectin (fFN)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Fetal heart rate monitoring (FHRM)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Fetal blood sampling (FBS)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: US imaging in late pregnancy
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Doppler velocimetry in low-risk pregnancy
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Tocolysis beyond 7 days
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Multiple course antenatal corticosteroids (BMZ)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Pulse oximetry
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Electrocardiogram ST-segment analysis
Number of subjects: 11
Study: 10427126

Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) combined with transcatheter arterial embolization (TAE) and percutaneous ethanol injection (PEI)
Number of subjects: 102

Group type: COMPARATOR
Intervention: No RT (control group)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) combined with TAE and PEI
Number of subjects: 102
Study: 7755070

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (60 mg/day)
Number of subjects: 1629

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1629

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Number of subjects: 1629

Group type: COMPARATOR
Intervention: No epidural anesthesia
Number of subjects: 1629
Study: 2088025

Group type: EXPERIMENTAL
Intervention: Topical tretinoin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Oral etretinate
Number of subjects: 20
Study: 314119

Group type: EXPERIMENTAL
Intervention: Group therapy
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 61
Study: 30575484

Group type: EXPERIMENTAL
Intervention: sorafenib (400‐mg tablet once daily)
Number of subjects: 87

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 87
Study: 27244862

Group type: EXPERIMENTAL
Intervention: Erythropoietin (Epo) 1000 U/kg intravenously
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 24898834

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 11685

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid
Number of subjects: 11685
Study: 22402913

Group type: EXPERIMENTAL
Intervention: HRV Biofeedback (BFB) training for 10 consecutive days for 20 min
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo group (motivational video clips for 10 consecutive days for 10 min)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (No Treatment)
Number of subjects: 30
Study: 20197017

Group type: EXPERIMENTAL
Intervention: Schisandra sphenanthera extract (SchE) co-administered with Tacrolimus (Tac) in Group A (same dose of Tac)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Schisandra sphenanthera extract (SchE) co-administered with Tacrolimus (Tac) in Group B (lower dose of Tac)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Schisandra sphenanthera extract (SchE) co-administered with Tacrolimus (Tac)
Number of subjects: 92
Study: 18182621

Group type: EXPERIMENTAL
Intervention: Interferon
Number of subjects: 347

Group type: COMPARATOR
Intervention: Medroxyprogesterone acetate
Number of subjects: 347
Study: 15942204

Group type: EXPERIMENTAL
Intervention: Electrogastrography (EGG) with water load test
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Electrogastrography (EGG)
Number of subjects: 20
Study: 11829008

Group type: EXPERIMENTAL
Intervention: Individually prescribed coloured overlays
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control filter
Number of subjects: 33
Study: 10980833

Group type: EXPERIMENTAL
Intervention: Implantable defibrillator
Number of subjects: 0
Study: 7595610

Group type: EXPERIMENTAL
Intervention: Bipap support (group II)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Palliative management (group I)
Number of subjects: 20
Study: 2279542

Group type: EXPERIMENTAL
Intervention: alpha interferon (IFN) therapy (1.8 MU/sm/daily for younger patients, 1.0 MU/daily for older patients) followed by splenectomy
Number of subjects: 115

Group type: COMPARATOR
Intervention: alpha interferon (IFN) therapy (1.8 MU/sm/daily for younger patients, 1.0 MU/daily for older patients) followed by observation
Number of subjects: 115
Study: 7002563

Group type: EXPERIMENTAL
Intervention: Prostacyclin (PGI2) intravenous infusion at doses up to 4 ng/kg per min
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Prostacyclin (PGI2) intravenous infusion at 4 ng/kg per min
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Prostacyclin (PGI2) intravenous infusion
Number of subjects: 6
Study: 30975057

Group type: EXPERIMENTAL
Intervention: Bacterial-binding dressing (DACC-impregnated surgical dressing)
Number of subjects: 543
Study: 27182005

Group type: EXPERIMENTAL
Intervention: Omarigliptin 5-100 mg single dose
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Omarigliptin 1-50 mg multiple once-weekly dose
Number of subjects: 100

Group type: COMPARATOR
Intervention: Omarigliptin (various doses)
Number of subjects: 100
Study: 26342062

Group type: EXPERIMENTAL
Intervention: Anodal (active) stimulation of 2 mA tDCS to the right dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anodal (active) stimulation of 2 mA tDCS to the left dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active stimulation of the left primary motor cortex
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation of the right DLPFC
Number of subjects: 0
Study: 23394494

Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia (TIVA) with propofol (group T)
Number of subjects: 3

Group type: COMPARATOR
Intervention: General inhalational anesthesia with sevoflurane (group S)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Regional anesthesia (group R)
Number of subjects: 3
Study: 21105991

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin and cisplatin (MVAC)
Number of subjects: 295
Study: 19671802

Group type: EXPERIMENTAL
Intervention: Ustekinumab (45 mg for patients <100 kg or 90 mg for patients >100 kg, administered subcutaneously; second dose at 4 weeks, then every 8-12 weeks based on response)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18038253

Group type: EXPERIMENTAL
Intervention: PRO 160/120 (160 mg Sabal fruit extract WS 1473 and 120 mg Urtica root extract WS 1031 per capsule, 2 x 1 capsule/day)
Number of subjects: 257

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 257
Study: 15506025

Group type: EXPERIMENTAL
Intervention: Cerec crowns with reduced stump preparations
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cerec endo crowns
Number of subjects: 20
Study: 10861146

Group type: EXPERIMENTAL
Intervention: Lidocaine treatment group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Bupivacaine treatment group
Number of subjects: 40
Study: 9092954

Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) at daily target dosages of 200-1,000 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topiramate (TPM)
Number of subjects: 0
Study: 8386650

Group type: EXPERIMENTAL
Intervention: Cisplatin combination chemotherapy
Number of subjects: 632
Study: 3964314

Group type: EXPERIMENTAL
Intervention: Arthritis self-management course led by laypersons
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Arthritis self-management course led by professionals
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 31566033

Group type: EXPERIMENTAL
Intervention: Psychoeducation intervention
Number of subjects: 35

Group type: COMPARATOR
Intervention: Conventional nursing
Number of subjects: 35
Study: 30361806

Group type: EXPERIMENTAL
Intervention: Intermediate adherence to statins (proportion of days of follow-up covered 41-80%)
Number of subjects: 6263

Group type: EXPERIMENTAL
Intervention: High adherence to statins (proportion of days of follow-up covered >80%)
Number of subjects: 6263
Study: 27117144

Group type: EXPERIMENTAL
Intervention: DHA supplementation in VLCK diet
Number of subjects: 29

Group type: COMPARATOR
Intervention: Isocaloric VLCK diet without DHA (control)
Number of subjects: 29
Study: 23965645

Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg co-administered with simvastatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CYP3A4/5 polymorphisms (extensive metabolizers)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Optimal simvastatin dose
Number of subjects: 0
Study: 22973094

Group type: EXPERIMENTAL
Intervention: Isometric peak torque
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Steep ramp anaerobic test (SRAT)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Eccentric peak torque at 90°/sec
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: TUG time
Number of subjects: 13
Study: 20550071

Group type: EXPERIMENTAL
Intervention: Automated chest percussion therapy (CPT) for 10 minutes
Number of subjects: 30
Study: 18600390

Group type: EXPERIMENTAL
Intervention: Combination of interferon-alpha (6 million units daily for 2 weeks, then three times weekly) plus lamivudine (100 mg daily) for 24 weeks followed by lamivudine alone for 28 weeks (n = 30)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Combination of interferon-alpha plus lamivudine
Number of subjects: 64

Group type: COMPARATOR
Intervention: Lamivudine monotherapy (n = 34)
Number of subjects: 64
Study: 15811483

Group type: EXPERIMENTAL
Intervention: Adherence clinic
Number of subjects: 33

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 33
Study: 12208711

Group type: EXPERIMENTAL
Intervention: LADARVision excimer laser system (LASIK) for spherical hyperopia
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: LADARVision excimer laser system (LASIK) for hyperopic astigmatism
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: LADARVision excimer laser system (LASIK) for mixed astigmatism
Number of subjects: 360
Study: 11040232

Group type: COMPARATOR
Intervention: Obese normotensive subjects
Number of subjects: 59

Group type: COMPARATOR
Intervention: Lean hypertensive subjects
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Obese hypertensive subjects
Number of subjects: 59
Study: 8997656

Group type: EXPERIMENTAL
Intervention: New toothbrush with filaments angled away from the head
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional toothbrush designs (3 types)
Number of subjects: 36
Study: 1612948

Group type: EXPERIMENTAL
Intervention: Chemotherapy regimen of two cycles of cisplatin, bleomycin, vindesine and mitomycin C (first trial, 100 patients)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Chemotherapy regimen of three cycles of cisplatin, 5‐fluorouracil by continuous infusion and vindesine (second trial, 108 patients)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Both chemotherapy regimens
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 208
Study: 6704275

Group type: EXPERIMENTAL
Intervention: naloxone 1.2 mg i.v.
Number of subjects: 30

Group type: COMPARATOR
Intervention: saline 3 ml (placebo)
Number of subjects: 30
Study: 31771797

Group type: EXPERIMENTAL
Intervention: Active Monitoring (AM)
Number of subjects: 2640
Study: 31219597

Group type: EXPERIMENTAL
Intervention: Genetic predisposition towards 3.6 years of additional education
Number of subjects: 11348

Group type: EXPERIMENTAL
Intervention: Genetic predisposition towards longer education
Number of subjects: 11348
Study: 27608536

Group type: EXPERIMENTAL
Intervention: Faith-based intervention including motivational interviewing sessions and church-based group activities
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 71
Study: 26790207

Group type: EXPERIMENTAL
Intervention: Heat-sensitive moxibustion added to FOLFOX chemotherapy regimen
Number of subjects: 60

Group type: COMPARATOR
Intervention: FOLFOX chemotherapy regimen alone (Control)
Number of subjects: 60
Study: 21823199

Group type: EXPERIMENTAL
Intervention: Group Cognitive-Behavioural Therapy (CBT)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Guided Self-Help (GSH)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Waiting List Condition
Number of subjects: 56
Study: 21506241

Group type: EXPERIMENTAL
Intervention: Peginterferon alfa‐2a (135 μg/week for 4 weeks and then 180 μg/week for 44 weeks) plus ribavirin (initial dose of 400 mg/day escalated to 1200 mg/day)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Observation (treatment initiated upon significant HCV recurrence)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Prophylaxis
Number of subjects: 115
Study: 17719752

Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 2641

Group type: COMPARATOR
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 2641

Group type: COMPARATOR
Intervention: SSRIs
Number of subjects: 2641
Study: 17252706

Group type: EXPERIMENTAL
Intervention: Generic glimepiride tablets (6 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Innovator glimepiride tablets (6 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 24
Study: 14616187

Group type: EXPERIMENTAL
Intervention: Levo-alpha acetylmethadol (LAAM)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 93